Topic: Policy: Indication Specific Pricing

Indication-specific pricing: pharmaceuticals in the United States health care system 

Dec 2015 | Policy Paper

The 2015 ICER Policy Summit convened an influential group of evidence policy leaders from insurers, pharmacy benefit management firms, and life science companies to discuss indication-specific pricing (ISP) of biopharmaceuticals and to explore the opportunities and challenges of ISP in the US health care system. Date of review: December 2015 For more information, please contact […]